USFDA gives tentative nod to Zydus Cadila for Pimavanserin capsules

The drug will be manufactured at the group’s formulation manufacturing facility at SEZ Ahmedabad.

110
USFDA
Picture: Pixabay

Last Updated on January 2, 2022 by The Health Master

Zydus Pharmaceuticals, Inc. has received tentative approval from the US Food and Drug Administration (USFDA) to market Pimavanserin capsules at a strength of 34 mg.

Pimavanserin is an atypical antipsychotic and is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, it added.

It further mentioned that the drug will be manufactured at the group’s formulation manufacturing facility at SEZ Ahmedabad.

USFDA gives tentative nod to Amphastar Pharma for Vasopressin injection

USFDA gives nod to Granules India for Prazosin HCL capsules

USFDA gives nod to Lupin for this drug to treat Kidney disease

USFDA gives nod to Lupin generic Azilsartan Medoxomil tablets

USFDA authorises first oral antiviral to treat COVID

USFDA approves expanded use of Amgen’s psoriasis drug

Meting for 19 FDCs permitted pre-1988 postponed

DCGI gives approval to Biological E for Corbevax

USFDA gives tentative nod to Amphastar Pharma for Vasopressin injection

NPPA fixes retail price of 2 formulations: December 2021

NPPA fixes retail price of 28 formulations: December 2021

NPPA extends price cap on liquid Medical Oxygen and Oxygen inhalation

CDSCO approves Corbevax, Covovax and Molnupiravir for restricted use

Nutraceutical sector concerned over FSSAI’s notification on Marketers

We must learn to live with Covid: WHO

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner